How much improvement in functioning is considered important by patients with active disease modifying anti-rheumatic drug refractory rheumatoid arthritis

被引：0
|
作者：
Singh, A [1 ]
Sato, R [1 ]
Wanke, L [1 ]
机构：
[1] Hlth Outcomes Assessment, Thousand Oaks, CA USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2003年 / 62卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：108 / 108
页数：1
相关论文
共 50 条
  • [21] Disease-modifying anti-rheumatic drug therapy and structural damage in early rheumatoid arthritis
    Mullan, RH
    Bresnihan, B
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2003, 21 (05) : S158 - S164
  • [22] Patient Preferences for Disease Modifying Anti-Rheumatic Drug Treatment of Rheumatoid Arthritis: A Systematic Review
    Durand, Caylib
    Eldoma, Maysoon
    Marshall, Deborah
    Hazlewood, Glen
    JOURNAL OF RHEUMATOLOGY, 2017, 44 (06) : 889 - 889
  • [23] Gene expression of Interleukin-18 in rheumatoid arthritis patients on disease modifying anti-rheumatic drug therapy
    Khalid, Sabeen
    Yousaf, Muhammad Javad
    Rashid, Amir
    Khan, Saleem Ahmad
    PAKISTAN JOURNAL OF MEDICAL SCIENCES, 2019, 35 (03) : 802 - 806
  • [24] Adverse drug reactions associated with the use of disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis
    Enrique Machado-Alba, Jorge
    Felipe Ruiz, Andres
    Enrique Machado-Duque, Manuel
    REVISTA PANAMERICANA DE SALUD PUBLICA-PAN AMERICAN JOURNAL OF PUBLIC HEALTH, 2014, 36 (06): : 396 - 401
  • [25] HOW REPRESENTATIVE OF THE RHEUMATOID ARTHRITIS (RA) PATIENT IS A GROUP ENTERED INTO A DISEASE MODIFYING ANTI-RHEUMATIC DRUG (DMARD) STUDY?
    Irvine, S.
    Hampson, R.
    Madhok, R.
    Capell, H. A.
    RHEUMATOLOGY, 2003, 42 : 96 - 97
  • [26] Utilization of biologic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis and cancer
    Xerxes Pundole
    Natalia V. Zamora
    Harish Siddhanamatha
    Heather Lin
    Jean Tayar
    Leung Cheuk Hong
    Liang Li
    Maria E. Suarez-Almazor
    Clinical Rheumatology, 2020, 39 : 787 - 794
  • [27] Use of disease-modifying anti-rheumatic drugs and cardiovascular events in patients with rheumatoid arthritis
    Kaminski, Matthew
    Shishehbor, Mehdi H.
    Gutierrez, Antonio
    Amini, Mohammad R.
    Coats, Walter
    Moghbelli, Meisam
    Askari, Arman T.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2008, 51 (10) : A370 - A370
  • [28] Utilization of biologic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis and cancer
    Pundole, Xerxes
    Zamora, Natalia V.
    Siddhanamatha, Harish
    Lin, Heather
    Tayar, Jean
    Hong, Leung Cheuk
    Li, Liang
    Suarez-Almazor, Maria E.
    CLINICAL RHEUMATOLOGY, 2020, 39 (03) : 787 - 794
  • [29] The anti-rheumatic effect of multiple synovectomy in patients with refractory rheumatoid arthritis
    Nakamura, H
    Nagashima, M
    Ishigami, S
    Wauke, K
    Yoshino, S
    INTERNATIONAL ORTHOPAEDICS, 2000, 24 (05) : 242 - 245
  • [30] Combined treatment with leflunomide and methotrexate for patients with disease-modifying anti-rheumatic drugs naive active rheumatoid arthritis
    Lee, S.
    Park, Y.
    Kang, Y.
    Nam, E.
    Kim, S.
    Lee, J.
    Yoo, W.
    Lee, S.
    Park, J.
    ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 : 342 - 342
12345